TABLE 1.
Clinico-pathological characteristics of patients.
| Variable | No. | % |
| Age | ||
| Median, range (year) | 64, 28-79 | |
| Gender | ||
| Male | 127 | 52.1 |
| Female | 117 | 47.9 |
| Side | ||
| Left | 151 | 61.9 |
| Right | 93 | 38.1 |
| Grading | ||
| G1/G2 | 41 | 16.8 |
| G3 | 203 | 83.2 |
| Lymphnodal involvementa | ||
| No | 86 | 35.2 |
| Yes | 134 | 54.9 |
| Unknown | 24 | 9.8 |
| pTa | ||
| T1/T2 | 43 | 19.6 |
| T3 | 150 | 68.2 |
| T4 | 27 | 12.3 |
| Unknown | 24 | 9.8 |
| No. of metastatic sites | ||
| 1 | 81 | 33.2 |
| ≥2 | 163 | 66.8 |
| RAS (K or N) | ||
| Mutated | 134 | 54.9 |
| Wild-type | 110 | 45.1 |
| BRAF | ||
| Mutated | 15 | 6.1 |
| Wild-type | 229 | 93.9 |
| Body-mass index | ||
| Normal | 124 | 50.8 |
| 25–29.9 kg/m2 (overweight) | 59 | 24.2 |
| >30.0 kg/m2 (obese) | 61 | 25.0 |
| Type 2 diabetes | ||
| Yes | 50 | 20.5 |
| No | 194 | 79.5 |
| Hypertension | ||
| Yes | 110 | 45.1 |
| No | 134 | 54.9 |
| No. of treatment lines | ||
| 1 | 12 | 4.9 |
| 2 | 26 | 10.7 |
| >2 | 206 | 84.4 |
| Previous adjuvant therapy | ||
| Yes | 126 | 51.6 |
| No | 118 | 48.4 |
| Type of treatment | ||
| Only CT | 29 | 11.9 |
| CT plus anti-VEGF | 106 | 43.3 |
| CT plus anti-EGFR | 109 | 44.7 |
aThe sum of cases does not correspond to the total number of patients because some of them (24) did not receive surgical removal of primary tumor.